New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic performance, its impacts, and its geographic footprint.


The report, "The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions," analyzes the sector's economic impact via employment, overall output, wages/benefits, and tax revenue.


Key takeaways from the report include:


  • The industry's economic impact, as measured by overall output, totaled more than $3.2 trillion in 2023. 
  • In 2023, the nation's bioscience industry employed nearly 2.3 million Americans across almost 150,000 U.S. business establishments and in every U.S. state. The sector indirectly supports nearly 8 million additional jobs.
  • The industry's employment has increased significantly, by nearly 15 percent since 2019, maintaining its long-term growth trend and well outpacing the nation's overall private sector job growth during this period.
  • Between 2019 and 2023, 49 states, DC, and Puerto Rico experienced net job growth in the bioscience industry.


"America’s bioscience sector is vital to addressing the world's most pressing challenges -- from pandemics and national security to preventative health and environmental sustainability. Industry leaders and researchers overcome tremendous obstacles every day to advance innovative solutions and help people lead healthier lives, and this report shows how the sector continues to enrich communities, create jobs, and grow economies across our great country," said John F. Crowley, BIO’s President & CEO. 


“For two decades now, this report series has shown the growth and impact of the bioscience industry on the economy. In the wake of the COVID-19 pandemic and economic downturns, it is clear that the biosciences remain a key sector of the growing innovation economy,” said Pete Pellerito, BIO Senior Policy Adviser for Federal and State Economic Development and Technology Transfer Initiatives.

"The bioscience industry's economic footprint extends to every U.S. state and region," said Ryan Helwig, Principal and Project Director with TEConomy Partners. "That means all parts of the country play a part in the industry's breakthroughs and advancements and benefit from its economic impact."


The state-by-state industry assessment is the eleventh in a biennial series, developed in partnership by TEConomy Partners and BIO, and studies the state of the U.S. bioscience industry and its associated innovation ecosystem at the national, state, and metropolitan area levels. The report includes individual fact sheets for all 50 states, the District of Columbia, and Puerto Rico, which can be found alongside the full report and map at www.bio.org/jobs.

February 20, 2026
Recognition highlights Brookhaven’s commitment to life sciences growth and biomanufacturing readiness Brookhaven, GA, Feb. 18, 2026 – The City of Brookhaven has been designated a BioReady Gold Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady Community program evaluates a community’s preparedness to support life sciences development across key areas, including zoning and permitting, utilities and infrastructure, workforce readiness, and coordination among local government and economic development partners. The Gold distinction represents a high level of readiness and alignment with industry needs. “Achieving Gold BioReady status underscores Brookhaven’s commitment to being a competitive destination for life sciences innovation and manufacturing,” said Aaron Szarowicz, City of Brookhaven Economic Development Director. “This designation reflects the intentional investments and partnerships we’ve built to support companies as they scale and create high-quality jobs in our community.” Brookhaven’s BioReady assessment highlighted the City’s modern infrastructure, strategic location within metro Atlanta, access to a skilled workforce, and collaborative approach between City leadership, regional partners, and the business community. Together, these assets position Brookhaven to support companies across the life sciences value chain—from research and development to scale-up and manufacturing. The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-zoned sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Brookhaven to compete more effectively for private investment and job creation. Georgia Life Sciences works to advance innovation, strengthen the workforce pipeline, and grow Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. For more information on the non-profit, membership-based organization, visit www.galifesciences.org . For more information about Brookhaven’s economic development initiatives, visit www.BrookhavenGA.gov/EconDev . ### Media Contact: Ann Marie Quill, Assistant Communications Director 404-205-3832 AnnMarie.Quill@BrookhavenGA.gov
February 18, 2026
Georgia Life Sciences Releases “Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector”
February 17, 2026
by Maria Saporta February 9, 2026
MORE POSTS